Variability in the Generation of Induced Pluripotent Stem Cells: Importance for Disease Modeling
Open accessThe DOI matches its Crossref record; 25 of the 25 references it cites were found in a registry or an index.
Abstract
In the field of disease modeling, induced pluripotent stem cells (iPSCs) have become an appealing choice, especially for diseases that do not have an animal model. They can be generated from patients with known clinical features and compared with cells from healthy controls to identify the biological bases of disease. This study was undertaken to determine the variability in iPSC lines derived from different individuals, with the aim of determining criteria for selecting iPSC lines for disease models. We generated and characterized 18 iPSC lines from eight donors and considered variability at three levels: (a) variability in the criteria that define iPSC lines as pluripotent cells, (b) variability in cell lines from different donors, and (c) variability in cell lines from the same donor. We found that variability in transgene expression and pluripotency marker levels did not prevent iPSCs from fulfilling all other criteria for pluripotency, including teratoma formation. We found low interindividual and interclonal variability in iPSCs that fulfilled the most stringent criteria for pluripotency, with very high correlation in their gene expression profiles. Interestingly, some cell lines exhibited reprogramming instability, spontaneously regressing from a fully to a partially reprogrammed state. This was associated with a low percentage of cells expressing the pluripotency marker stage-specific embryonic antigen-4. Our study shows that it is possible to define a similar "ground state" for each cell line as the basis for making patient versus control comparisons, an essential step in order to identify disease-associated variability above individual and cell line variability.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Reprogramming, for example, a given somatic cell type from a given donor, using a given reprogramming method and culture platform, may give rise to iPSC colonies that are different in their expansion rate, robustness (the tendency to spontaneously differentiate in culture), and potential to be differentiated directly to specific lineages [56,57,58,59,60].”
From Overcoming the Variability of iPSCs in the Manufacturing of Cell-Based Therapies (2023) · cites this paper as [57]
In the citing paper
“Nevertheless, keeping the above parameters the same still results in iPSC colonies that are different from each other.”
From Overcoming the Variability of iPSCs in the Manufacturing of Cell-Based Therapies (2023) · cites this paper as [57]
Citations
Cites
Core Transcriptional Regulatory Circuitry in Human Embryonic Stem Cells
Boyer, L. A., Lee, T. I., Cole, M. F., Johnstone, S. E., Levine, S. S., Zucker, J. P., Guenther, M. G., Kumar, R. M., Murray, H. L., Jenner, R. G., et al. (2005) · Cell · doi:10.1016/j.cell.2005.08.020 · Cited by 4,505
Disease-Specific Induced Pluripotent Stem Cells.
Park, I.-H., Arora, N., Huo, H., Maherali, N., Ahfeldt, T., Shimamura, A., Lensch, M. W., Cowan, C., Hochedlinger, K., & Daley, G. Q. (2008) · Cell · doi:10.1016/j.cell.2008.07.041 · Cited by 2,196
lumi: a pipeline for processing Illumina microarray
Du, P., Kibbe, W. A., & Lin, S. M. (2008) · Bioinformatics · doi:10.1093/bioinformatics/btn224 · Cited by 2,019
Dimos, J. T., Rodolfa, K. T., Niakan, K. K., Weisenthal, L. M., Mitsumoto, H., Chung, W., Croft, G. F., Saphier, G., Leibel, R., Goland, R., et al. (2008) · Science · doi:10.1126/science.1158799 · Cited by 1,962
Soldner, F., Hockemeyer, D., Beard, C., Gao, Q., Bell, G. W., Cook, E. G., Hargus, G., Blak, A., Cooper, O., Mitalipova, M., et al. (2009) · Cell · doi:10.1016/j.cell.2009.02.013 · Cited by 1,549
Induced pluripotent stem cells from a spinal muscular atrophy patient
Ebert, A. D., Yu, J., Rose, F. F., Mattis, V. B., Lorson, C. L., Thomson, J. A., & Svendsen, C. N. (2009) · Nature · doi:10.1038/nature07677 · Cited by 1,441
Modelling schizophrenia using human induced pluripotent stem cells
Brennand, K. J., Simone, A., Jou, J., Gelboin-Burkhart, C., Tran, N., Sangar, S., Li, Y., Mu, Y., Chen, G., Yu, D., et al. (2011) · Nature · doi:10.1038/nature09915 · Cited by 1,375
Epigenetic reprogramming and induced pluripotency
Hochedlinger, K., & Plath, K. (2009) · Development · doi:10.1242/dev.020867 · Cited by 553
Elite and stochastic models for induced pluripotent stem cell generation
Yamanaka, S. (2009) · Nature · doi:10.1038/nature08180 · Cited by 515
A functionally characterized test set of human induced pluripotent stem cells
Boulting, G. L., Kiskinis, E., Croft, G. F., Amoroso, M. W., Oakley, D. H., Wainger, B. J., Williams, D. J., Kahler, D. J., Yamaki, M., Davidow, L., et al. (2011) · Nature Biotechnology · doi:10.1038/nbt.1783 · Cited by 489
Cited by
Mechanisms and models of somatic cell reprogramming
Buganim, Y., Faddah, D. A., & Jaenisch, R. (2013) · Nature Reviews Genetics · doi:10.1038/nrg3473 · Cited by 456
“Rather, these data suggested that the extent of variations seen between ESCs and iPSCs were similar to variations seen within different ESC lines or within different iPSC lines 120 .”
Best Practices for Translational Disease Modeling Using Human iPSC-Derived Neurons
Engle, S. J., Blaha, L., & Kleiman, R. J. (2018) · Neuron · doi:10.1016/j.neuron.2018.10.033 · Cited by 142
Pluripotent stem cells in neuropsychiatric disorders
Soliman, M. A., Aboharb, F., Zeltner, N., & Studer, L. (2017) · Molecular Psychiatry · doi:10.1038/mp.2017.40 · Cited by 143
Comparison and Optimization of hiPSC Forebrain Cortical Differentiation Protocols
Muratore, C. R., Srikanth, P., Callahan, D. G., & Young-Pearse, T. L. (2014) · PLoS ONE · doi:10.1371/journal.pone.0105807 · Cited by 111
Rohart, F., Eslami, A., Matigian, N., Bougeard, S., & Lê Cao, K.-A. (2017) · BMC Bioinformatics · doi:10.1186/s12859-017-1553-8 · Cited by 108
Cao, K. L., Rohart, F., McHugh, L. C., Korn, O., & Wells, C. A. (2014) · Genomics · doi:10.1016/j.ygeno.2014.03.001 · Cited by 86
Stemformatics: Visualisation and sharing of stem cell gene expression
Wells, C. A., Mosbergen, R., Korn, O., Choi, J., Seidenman, N., Matigian, N. A., Vitale, A. M., & Shepherd, J. (2013) · Stem Cell Research · doi:10.1016/j.scr.2012.12.003 · Cited by 77
“Further study of the potentially secreted products across the four hESC The utility of Stemformatics as an exploratory tool for stem cell researchers is highlighted by recent publications of Stemformatics users (Nayler et al., 2012) and (Vitale et al., 2012).”
BackgroundCorneal cell therapy: with iPSCs, it is no more a far-sight
Chakrabarty, K., Shetty, R., & Ghosh, A. (2018) · Stem cell research & therapeutics · doi:10.1186/s13287-018-1036-5 · Cited by 65
van Mil, A., Balk, G. M., Neef, K., Buikema, J. W., Asselbergs, F. W., Wu, S. M., Doevendans, P. A., & Sluijter, J. P. G. (2018) · Cardiovascular Research · doi:10.1093/cvr/cvy208 · Cited by 65
Prem, S., Millonig, J. H., & DiCicco-Bloom, E. M. (2020) · Advances in neurobiology · doi:10.1007/978-3-030-45493-7_5 · Cited by 68
Hasegawa, Y., Taylor, D. M., Ovchinnikov, D. A., Wolvetang, E. J., de Torrenté, L., & Mar, J. C. (2015) · PLoS Genetics · doi:10.1371/journal.pgen.1005428 · Cited by 66
Srikanth, P., & Young-Pearse, T. L. (2014) · Journal of Neurogenetics · doi:10.3109/01677063.2014.881358 · Cited by 57
“…Hester et al., 2011; Hu et al., 2010; Hu & Zhang, 2009; H. Lee et al., 2007b; X.-J. Li et al., 2005; 2008; Nizzardo et al., 2010; Roy et al., 2005; Wada et al., 2009; Zeng et al., 2010 Dopaminergic neurons Chambers et al., 2009; Cho et al., 2008a; Cho et al., 2008b; Cooper et al., 2010; Elkabetz…”
A patient-derived stem cell model of hereditary spastic paraplegia with SPAST mutations
Abrahamsen, G., Fan, Y., Matigian, N., Wali, G., Bellette, B., Sutharsan, R., Raju, J., Wood, S. A., Veivers, D., Sue, C. M., et al. (2013) · Disease Models & Mechanisms · doi:10.1242/dmm.010884 · Cited by 59
Balafkan, N., Mostafavi, S., Schubert, M., Siller, R., Liang, K. X., Sullivan, G. J., & Bindoff, L. A. (2020) · Scientific Reports · doi:10.1038/s41598-020-73656-2 · Cited by 56
Drug discovery using induced pluripotent stem cell models of neurodegenerative and ocular diseases
Hung, S. S. C., Khan, S., Lo, C. Y.-W., Hewitt, A. W., & Wong, R. C. B. (2017) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2017.02.026 · Cited by 49
Building a microphysiological skin model from induced pluripotent stem cells
Guo, Z., Higgins, C. A., Gillette, B. M., Itoh, M., Umegaki, N., Gledhill, K., Sia, S. K., & Christiano, A. M. (2013) · Stem Cell Research & Therapy · doi:10.1186/scrt363 · Cited by 41
Kim, K. H., Liu, J., Galvin, R. J. S., Dage, J. L., Egeland, J. A., Smith, R. C., Merchant, K., & Paul, S. M. (2015) · PLoS ONE · doi:10.1371/journal.pone.0142693 · Cited by 41
Nassor, F., Jarray, R., Biard, D. S. F., Maïza, A., Papy-García, D., Pavoni, S., Deslys, J., & Yates, F. (2020) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2020.00014 · Cited by 42
Sridhar, A., Ohlemacher, S. K., Langer, K. B., & Meyer, J. S. (2016) · Stem Cells Translational Medicine · doi:10.5966/sctm.2015-0093 · Cited by 39
Lupo, K. B., Moon, J.-I., Chambers, A. M., & Matosevic, S. (2021) · Cytotherapy · doi:10.1016/j.jcyt.2021.05.001 · Cited by 42
Neural organoids for disease phenotyping, drug screening and developmental biology studies
Hartley, B. J., & Brennand, K. J. (2017) · Neurochemistry International · doi:10.1016/j.neuint.2016.10.004 · Cited by 38
Xie, Y., Ng, N. N., Safrina, O., Ramos, C. M., Ess, K. C., Schwartz, P. H., Smith, M. A., & O’Dowd, D. K. (2019) · Neurobiology of Disease · doi:10.1016/j.nbd.2019.104627 · Cited by 36
Addressing Variability and Heterogeneity of Induced Pluripotent Stem Cell-Derived Cardiomyocytes
Biendarra‐Tiegs, S. M., Secreto, F. J., & Nelson, T. J. (2019) · Advances in experimental medicine and biology · doi:10.1007/5584_2019_350 · Cited by 39
Human stem cell-based disease modeling: prospects and challenges
Johnson, J. Z., & Hockemeyer, D. F. (2015) · Current Opinion in Cell Biology · doi:10.1016/j.ceb.2015.10.007 · Cited by 34
“Current Opinion in Cell Biology 2015, 37:84–90 A significant challenge in iPSC-based disease modeling lies in the fact that each disease-specific iPSC line is genetically distinct due to the genetic variability among patients [6].”
BackgroundAlzheimer’s disease: phenotypic approaches using disease models and the targeting of tau protein
Lauretti, E., & Praticò, D. (2020) · Expert Opinion on Therapeutic Targets · doi:10.1080/14728222.2020.1737012 · Cited by 32
“ability to model the late-onset disease since differentiated cells are often functionally immature [61] and tau generated by stem-cell-derived neurons remains in the fetal state (i.”
BackgroundOvercoming the Variability of iPSCs in the Manufacturing of Cell-Based Therapies
Nath, S. C., Menendez, L., & Friedrich Ben-Nun, I. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms242316929 · Cited by 35
Patient-derived stem cells: pathways to drug discovery for brain diseases
Mackay‐Sim, A. (2013) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2013.00029 · Cited by 34
“This work was funded in part by grants from the Hereditary Spastic Paraplegia Research Foundation Inc., the National Health and Medical Research Council of Australia, and the Australian Government Department of Health and Ageing.”
BackgroundMethodDNA methylation in schizophrenia in different patient-derived cell types
Vitale, A. M., Matigian, N., Cristino, A. S., Nones, K., Ravishankar, S., Bellette, B., Fan, Y., Wood, S. A., Wolvetang, E. J., & Mackay‐Sim, A. (2017) · Schizophrenia · doi:10.1038/s41537-016-0006-0 · Cited by 33
Engineering in vitro human neural tissue analogs by 3D bioprinting and electrostimulation
Warren, D., Tomaskovic‐Crook, E., Wallace, G. G., & Crook, J. M. (2021) · APL Bioengineering · doi:10.1063/5.0032196 · Cited by 32
Gene Expression Variability as a Unifying Element of the Pluripotency Network
Mason, E. A., Mar, J. C., Laslett, A. L., Pera, M. F., Quackenbush, J. F., Wolvetang, E. J., & Wells, C. A. (2014) · Stem Cell Reports · doi:10.1016/j.stemcr.2014.06.008 · Cited by 28
“These cells were described as a mixed population of progenitor cells not able to produce all germ layers in a teratoma (Vitale et al., 2012).”
BackgroundInduced Pluripotent Stem Cell-Derived Corneal Cells: Current Status and Application
Mahmood, N., Suh, T. C., Ali, K. M., Sefat, E., Jahan, U. M., Huang, Y., Gilger, B. C., & Gluck, J. M. (2022) · Stem Cell Reviews and Reports · doi:10.1007/s12015-022-10435-8 · Cited by 28
“This causes a limitation of variability between cells derived from different patients [111].”
BackgroundPushp, P., Nogueira, D. E. S., Rodrigues, C. A. V., Ferreira, F. C., Cabral, J. M. S., & Gupta, M. K. (2020) · Stem Cell Reviews and Reports · doi:10.1007/s12015-020-10061-2 · Cited by 27
Identification of marker genes to monitor residual iPSCs in iPSC-derived products
Lemmens, M., Perner, J., Potgeter, L., Zogg, M., Thiruchelvam, S., Müller, M. M., Doll, T., Werner, A., Gilbart, Y., Couttet, P., et al. (2022) · Cytotherapy · doi:10.1016/j.jcyt.2022.09.010 · Cited by 25
Holtzinger, A., Streeter, P. R., Sarangi, F., Hillborn, S., Niapour, M., Ogawa, S., & Keller, G. M. (2015) · Development · doi:10.1242/dev.121020 · Cited by 29
“Despite this progress, efficiencies of differentiation vary considerably between different hPSC lines (Toivonen et al., 2013b; Vitale et al., 2012), even with the most advanced protocols, and end-stage populations are immature and, in some instances, contaminated with other cell types.”
BackgroundCustomizable, engineered substrates for rapid screening of cellular cues
Huethorst, E., Cutiongco, M. F. A., Campbell, F. A., Saeed, A., Love, R., Reynolds, P. M., Dalby, M. J., & Gadegaard, N. (2019) · Biofabrication · doi:10.1088/1758-5090/ab5d3f · Cited by 24
“As this value is a constant, the amendment is simple: For comparison to bulk substrates, the shear modulus and the Young ’ s modulus are related by the Poisson ’ s ratio, providing that the substrate is, or can be treated as, isotropic: where ν is Poisson ’ s ratio of the material.”
BackgroundSystematic assessment of variability in the proteome of iPSC derivatives
Beekhuis-Hoekstra, S. D., Watanabe, K., Werme, J., de Leeuw, C. A., Paliukhovich, I., Li, K. W., Koopmans, F., Smit, A. B., Posthuma, D., & Heine, V. M. (2021) · Stem Cell Research · doi:10.1016/j.scr.2021.102512 · Cited by 23
“Although interclonal variability is expected to be lower than variability between donors (since clones are genetically identical), this has actually been shown to vary (Vitale, 2012; Kytt ¨ al ¨ a et al., 2016; Rouhani, 2014; Schwartzentruber, 2018).”
InfluentialSteichen, C., Si‐Tayeb, K., Wulkan, F., Crestani, T., Rosas, G., Dariolli, R., Pereira, A. C., & Krieger, J. E. (2017) · Current Protocols in Human Genetics · doi:10.1002/cphg.26 · Cited by 24
Schuster, J., Halvardson, J., Lorenzo, L. P. E., Ameur, A., Sobol, M., Raykova, D., Annerén, G., Feuk, L., & Dahl, N. (2015) · Cellular Reprogramming · doi:10.1089/cell.2015.0009 · Cited by 22
“However, recent studies have observed heterogeneity between iPSC lines derived from different individuals on the basis of mRNA expression arrays and flow cytometry data (Mills et al., 2013; Vitale et al., 2012).”
Wood, K., Rowlands, C. F., Thomas, H. B., Woods Jon, S., O’Flaherty, J., Douzgou, S., Kimber, S. J., Newman, W. G., & O’Keefe, R. T. (2020) · PLoS ONE · doi:10.1371/journal.pone.0233582 · Cited by 23
“This finding is in agreement with previous work which has shown greater disparity between disease-affected and disease-unaffected differentiated cells than iPSCs [87,88].”
ResultInduced pluripotent stem cells from subjects with Lesch-Nyhan disease
Sutcliffe, D. J., Dinasarapu, A. R., Visser, J. E., den Hoed, J., Seifar, F., Joshi, P. K., Ceballos-Picot, I., Sardar, T. A., Hess, E. J., Sun, Y. V., et al. (2021) · Scientific Reports · doi:10.1038/s41598-021-87955-9 · Cited by 23
Rad, M. A., Mahmodi, H., Filipe, E. C., Cox, T. R., Kabakova, I. V., & Tipper, J. L. (2021) · Bioprinting · doi:10.1016/j.bprint.2021.e00179 · Cited by 26
Current Methods and Challenges in the Comprehensive Characterization of Human Pluripotent Stem Cells
Asprer, J. S. T., & Lakshmipathy, U. (2014) · Stem Cell Reviews and Reports · doi:10.1007/s12015-014-9580-6 · Cited by 27
Pluripotent Stem Cells to Model Degenerative Retinal Diseases: The RPE Perspective
Dalvi, S., Galloway, C. A., & Singh, R. (2019) · Advances in experimental medicine and biology · doi:10.1007/978-3-030-28471-8_1 · Cited by 21
Modeling Inborn Errors of Hepatic Metabolism Using Induced Pluripotent Stem Cells
Pournasr, B., & Duncan, S. A. (2017) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.117.309199 · Cited by 17
Mantripragada, V. P., Luangphakdy, V., Hittle, B., Powell, K. A., & Muschler, G. F. (2020) · Cytotechnology · doi:10.1007/s10616-020-00403-w · Cited by 16
Modeling APOE ε4 familial Alzheimer’s disease in directly converted 3D brain organoids
Kim, Y.-K., Kim, H., Cho, B., An, S., Kang, S., Kim, S., & Kim, J. (2024) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2024.1435445 · Cited by 16
Vo, Q. D., Nakamura, K., Saito, Y., Akagi, S., Miyoshi, T., & Yuasa, S. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26114984 · Cited by 13
MacArthur, C. C., Pradhan, S. K., Wetton, N., Zarrabi, A., Dargitz, C., Sridharan, M., Jackson, S. M., Pickle, L., & Lakshmipathy, U. (2019) · Regenerative Medicine · doi:10.2217/rme-2018-0148 · Cited by 11
Zlotnik, D., Rabinski, T., Halfon, A., Anzi, S., Plaschkes, I., Benyamini, H., Nevo, Y., Gershoni, O. Y., Rosental, B., Hershkovitz, E., et al. (2022) · Stem Cell Reports · doi:10.1016/j.stemcr.2022.07.010 · Cited by 12
“Since iPSCs are prone to variability across different lines (Vitale et al., 2012), we also used the CRISPR-Cas9 system to generate POR-depleted isogenic lines.”
MethodUtilization of stem cells to model Parkinson's disease – current state and future challenges
Hillje, A., & Schwamborn, J. C. (2016) · Future Neurology · doi:10.2217/fnl.16.7 · Cited by 8
Tomaskovic‐Crook, E., Guerrieri-Cortesi, K., & Crook, J. M. (2021) · Brain Research Bulletin · doi:10.1016/j.brainresbull.2021.07.004 · Cited by 9
Torriano, S., Baulier, E., Diaz, A. G., Corneo, B., & Farber, D. B. (2022) · The CRISPR Journal · doi:10.1089/crispr.2021.0110 · Cited by 9
Belle, K. C., Shabazz, F. S., Nuytemans, K., Davis, D. A., Ali, A., Young, J. L., Scott, W. K., Mash, D. C., Vance, J. M., & Dykxhoorn, D. M. (2016) · Neuroscience Letters · doi:10.1016/j.neulet.2016.10.065 · Cited by 7
Charneca, J., Matias, A. C., Escapa, A. L., Fernandes, C., Alves, A., Santos, J. M. A., Nascimento, R., & Bragança, J. (2017) · Experimental Cell Research · doi:10.1016/j.yexcr.2017.07.002 · Cited by 7
“The reprogramming often generates partially reprogrammed cells or pre-iPSC which self-renew in culture [10–13], and fully reprogrammed iPSC are sometimes unstable and transit into a partially reprogrammed state [14].”
BackgroundAli, H. R. W., Suliman, S., Osman, T., Carrasco, M., Bruland, O., Costea, D. E., Ræder, H., & Mustafa, K. (2023) · Stem Cell Research & Therapy · doi:10.1186/s13287-023-03403-7 · Cited by 6
Pluripotent stem cells as a model to study non-coding RNAs function in human neurogenesis
Benchoua, A., & Peschanski, M. (2013) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2013.00140 · Cited by 6
“…profiles, between iPSC and hESC, suggesting that, next to the disease context, iPSC behavior may also be influenced by the technique and efficiency of reprograming as well as by the cell type from which the iPSC line was produced (Chin et al., 2009; Marchetto et al., 2009; Vitale et al., 2012).”
BackgroundGetachew, H., Mehrotra, S., Kaur, T., Fernández‐Godino, R., Pierce, E. A., & Garita‐Hernandez, M. (2025) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2025.101452 · Cited by 4
Choi, D.-K., Kim, Y.-K., HoonYu, J., Min, S., & Park, S.-W. (2021) · Progress in molecular biology and translational science · doi:10.1016/bs.pmbts.2021.01.020 · Cited by 5
Salazar-Noratto, G. E., Nations, C. C., Stevens, H. Y., Xu, M., Gaynard, S., Dooley, C., de Nijs, N., McDonagh, K., Shen, S., Willimon, S. C., et al. (2023) · Stem Cells Translational Medicine · doi:10.1093/stcltm/szad018 · Cited by 3
“40-43 Therefore, it was necessary to investigate the UPR of JOCD-iMSCs in a controlled environment.”
Kuczynska, Z., Neglur, P. K., Metin, E., Liput, M., Zychowicz, M., Zayat, V., Krześniak, N. E., Bużańska, L., & Kot, M. (2024) · Folia Neuropathologica · doi:10.5114/fn.2024.134026 · Cited by 3
Proteomic and functional comparison between human induced and embryonic stem cells
Brenes, A. J., Griesser, E., Sinclair, L. V., Davidson, L., Prescott, A. R., Singh, F., Hogg, E. K. J., Espejo-Serrano, C., Jiang, H., Yoshikawa, H., et al. (2024) · eLife · doi:10.7554/elife.92025.3 · Cited by 8
Dinasarapu, A. R., Sutcliffe, D. J., Grychowski, L., Ozel, E., Thite, A., Visser, J. E., Hess, E. J., Kolk, S. M., & Jinnah, H. A. (2025) · Stem Cells Translational Medicine · doi:10.1093/stcltm/szaf032 · Cited by 4
“4,8,10,11,13,35 Potential iPSC colonies are then isolated from this batch by manual scraping of visible colonies or the sample is replated for isolation of individual colonies.”
Dinasarapu, A. R., Sutcliffe, D. J., Ozel, E., Thite, A., Grychowski, L., Visser, J. E., Hess, E. J., Kolk, S. M., & Jinnah, H. A. (2025) · Stem Cells Translational Medicine · doi:10.1093/stcltm/szaf065 · Cited by 3
Filippich, C., Wolvetang, E. J., & Mowry, B. J. (2013) · Schizophrenia Bulletin · doi:10.1093/schbul/sbt103 · Cited by 4
Generation of a CHIP isogenic human iPSC-derived cortical neuron model for functional proteomics
Dias, C., Nita, E., Faktor, J., Hernychová, L., Kunath, T., & Ball, K. L. (2022) · STAR Protocols · doi:10.1016/j.xpro.2022.101247 · Cited by 2
Frega, M., Mossink, B., Linda, K., Keller, J., Schubert, D., & Kasri, N. N. (2018) · IEEE International Symposium on Circuits and Systems proceedings · doi:10.1109/iscas.2018.8351848 · Cited by 2
“Moreover, as iPSCs are genetically identical to the donor, iNeurons differentiated from patient-derived iPSCs provide a disease-permissive genetic context for the study of disease etiology and progression [19-21].”
BackgroundWells, M. F., Guss, E. J., Zhou, H., Sun, B. Q., Martínez, H., The NYSCF Global Stem Cell Array Team, Akopian, V., Noggle, S., Paull, D. J., Moore, J. C., et al. (2023) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2023.07.07.548182 · Cited by 2
Proteomic and functional comparison between human induced and embryonic stem cellsPreprint
Brenes, A. J., Griesser, E., Sinclair, L. V., Davidson, L., Prescott, A. R., Singh, F., Hogg, E. K. J., Espejo-Serrano, C., Jiang, H., Yoshikawa, H., et al. (2024) · eLife · doi:10.7554/elife.92025.1 · Cited by 2
Optimizing differentiation of human pluripotent stem cells towards corneal epithelium
Jouppila, J. (2016) · Tampere University Institutional Repository (Tampere University)
Induced Pluripotent Stem Cells
van Mil, A., Neef, K., Balk, G. M., Buikema, J. W., Sluijter, J. P. G., & Doevendans, P. A. (2020) · Springer eBooks · doi:10.1007/978-3-030-45457-9_26
Lakshmipathy, U., MacArthur, C. C., Sridharan, M., & Quintanilla, R. H. (2017) · doi:10.1002/9781119394372.ch4
Ali, H. R. W., Suliman, S., Osman, T., Carrasco, M., Bruland, O., Costea, D. E., Ræder, H., & Mustafa, K. (2023) · Research Square · doi:10.21203/rs.3.rs-2187505/v1
Flandes‐Iparraguirre, M. (2023) · Depósito Académico Digital Universidad de Navarra (University of Navarra) · doi:10.15581/10171/69152 · Cited by 1
Ali, H. R. W., Suliman, S., Osman, T., Carrasco, M., Bruland, O., Costea, D. E., Ræder, H., & Mustafa, K. (2023) · Figshare · doi:10.6084/m9.figshare.23916849
Proteomic and functional comparison between human induced and embryonic stem cellsPreprint
Brenes, A. J., Griesser, E., Sinclair, L. V., Davidson, L., Prescott, A. R., Singh, F., Hogg, E. K. J., Espejo-Serrano, C., Jiang, H., Yoshikawa, H., et al. (2024) · eLife · doi:10.7554/elife.92025.2 · Cited by 1
Simkin, D., Wafa, S. M. A., Gharib, M., Marshall, K. A., Yang, Y., Laux, L. C., George, A. L., & Kiskinis, E. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.07.26.666977 · Cited by 1
“…in accordance with prior studies that have highlighted the importance of genetic background on neuronal differentiation propensity and maturation 66,67 , although our analysis provides the first direct evidence that genetic background significantly shapes of neurons Importantly, while we found a…”
Modeling Schizophrenia by Altering cAMP Signaling in Human Neurons
Nallapati, C. S. (2013) · Deep Blue (University of Michigan)
Ali, H. R. W., Suliman, S., Osman, T. A.-H., Carrasco, M., Bruland, O., Costea, D.-E., Ræder, H., & Mustafa, K. (2023) · Figshare · doi:10.6084/m9.figshare.23916846
In Vitro Models of Neurodegenerative Diseases
Saleh, A., & Becker, E. B. E. (2026) · Contemporary clinical neuroscience · doi:10.1007/978-3-032-18296-8_6
Metadata
- Authors
- Vitale, A. M., Matigian, N. A., Ravishankar, S., Bellette, B., Wood, S. A., Wolvetang, E. J., & Mackay-Sim, A.
- Affiliations
- Griffith University (AU)
- The University of Queensland (AU)
- National Centre for Adult Stem Cell Research, Eskitis Institute for Cell and Molecular Therapies, Griffith University, Brisbane, Queensland, Australia
- Venue
- Stem Cells Translational Medicine
- Publisher
- Oxford University Press (OUP)
- Published
- 2012-09-01
- Volume
- 1
- Issue
- 9
- Pages
- 641-650
- ISSN
- 2157-6564 (ISSN-L)
- 2157-6580
- PMC
- PMC3659735
- OpenAlex
- W2107597848
- Cited by
- 79
- References
- 25
- Citations by year
- 2026: 1 · 2025: 5 · 2024: 6 · 2023: 7 · 2022: 5 · 2021: 7 · 2020: 8 · 2019: 5 · 2018: 4 · 2017: 8 · 2016: 5 · 2015: 5 · 2014: 5 · 2013: 6 · 2012: 2
- FWCI
- 2.31
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- academic.oup.com/journals/pages/open_access/funder_policies/chorus/standard_publication_model (vor)
- Locations
- Stem Cells Translational Medicine (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Griffith Research Online (submittedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Pluripotent Stem Cells Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cell Biology › Mesenchymal stem cell research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › CRISPR and Genetic Engineering
- Keywords
- induced pluripotent stem cells, disease modeling, transgene expression, stem cell markers, gene expression profiles, teratoma formation
- MeSH terms
- Adult, Animals, Cell Differentiation, Cell Line, Cells, Cultured, Female, Fibroblasts, Humans, Male, Middle Aged, Schizophrenia, Teratoma, Genetic Variation, Biomarkers, Gene Expression Profiling, Mice, Young Adult, Induced Pluripotent Stem Cells, Cellular Reprogramming
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.